Burning Rock Biotech Limited Q3 FY2023 earnings call

Management Statement and Operational Highlights:

• Business construction: Started from therapy selection and aim to expand to early detection, MRD, and biopharma.
• Breakeven goal: Reached breakeven in Q2 non-GAAP profit minus SG&A, Q3 impacted by industry disruption but still moving towards breakeven.
• Therapy selection: In-hospital model continued growth with 10% y-o-y revenue growth despite industry disruption, while central lab model was impacted.
• MRD: MEDAL study for lung cancer published in Cancer Cell as a big milestone, with other studies like colon cancer ongoing.
• Biopharma: Despite struggles in biopharma capital market, had strong growth with 31% y-o-y revenue growth and growing backlog.
• Early detection: Got BDD from NMPA, being the only multi-cancer early detection product with BDD from both FDA and NMPA.

Segment Performance:

• In-hospital model: In-hospital revenues had a 10% year-on-year growth.
• Central lab model: Impacted negatively with a 31% year-on-year decline.
• Biopharma: Revenue growth up 31% year-on-year, backlog still growing, and signed a CDx contract with BI.
• MRD: Strong clinical validation publications, including the MEDAL study for lung cancer published in Cancer Cell, with other studies like colon cancer underway.
• Early detection: Got a Breakthrough Device Designation granted by China National Medical Products Administration (NMPA), and is the only multi-cancer early detection product to receive BDD from both FDA and NMPA.

Guidance:

• Breakeven: Set goal to breakeven in non-GAAP profit minus SG&A, reached in Q2, Q3 impacted by industry disruption but expecting to turn positive again in future quarters.
• Cash position: Cash outflow in 2023 was RMB249 million, significantly below guidance, with cash runway of more than three years based on cash balance of RMB637 million at end of period.

Risks:

• Industry disruption: Impacted Q3 results, with cancellation of medical conferences and meetings causing volatility in profit, though expecting this to pass by end of year.

Question and Answer: There are no explicit question and answer exchanges in the provided transcript.